Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex And Moderna Post Strong 2026 Results As Billion-Dollar Deals Reshape A Market Headed For USD 6.34 Trillion By 2035


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Regeneron Grows 36%, Gilead Spends About USD 12.7 Billion on Four Deals and Pharma Buyers Race to Refill Pipelines: Precedence Research Company Intelligence on Leaders, Investments and Developments

Ottawa, Nov. 17, 2026 (GLOBE NEWSWIRE) --

The global biotechnology market is valued at USD 2.02 trillion in 2026 and is projected to reach USD 6.34 trillion by 2035 at a CAGR of 13.61%. Leading biotech companies raised their 2026 outlooks after third-quarter results, while large drugmakers announced acquisitions and collaborations worth tens of billions of dollars.

Precedence Research today released updated company intelligence on the global biotechnology market

The leading biotech companies delivered strong third-quarter 2026 results. Amgen's revenue rose 8% to USD 10.4 billion, Gilead's product sales grew 13% to USD 8.3 billion, Regeneron's revenue climbed 36% to USD 5.1 billion, Vertex grew 12% to USD 3.44 billion and Moderna's revenue rose 29%. Most raised their full-year guidance.

At the same time, 2026 has become one of the busiest years for biotech dealmaking. Gilead announced four deals with about USD 12.7 billion in upfront payments, including Arcellx, Sun Pharma agreed to acquire Organon for USD 11.75 billion, GSK agreed to buy Nuvalent for USD 10.6 billion, and Regeneron expanded its antibody collaboration with Sanofi for USD 1 billion upfront and up to USD 7 billion in milestones. This release profiles the top companies, their latest performance, and what their investments mean for the market through 2035.

Full report:

Request a sample:

Market at a Glance



Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher



Figure 1: Biotechnology Market Snapshot

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Bio-pharmacy, the part of the market made up of biotech medicines, holds 42% of revenue (about USD 848 billion in 2026, modeled on the published share), which is why the leading biotech drug companies are the focus of this release. Bioinformatics grows fastest as AI

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Top Companies in the Biotechnology Market



Figure 2: Top Biotechnology Companies, Q3 2026 Results

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Q3 2026 Revenue Key Growth Drivers 2026 Outlook / Strategy
Amgen USD 10.4B (+8%) Repatha USD 1.09B (+37%), Evenity +39%, Tezspire +43%, Imdelltra +128% Revenue guide USD 38.9–39.7B; MariTide in Phase 3
Gilead Sciences USD 8.3B; product sales +13% HIV USD 6.2B (+18%); Biktarvy USD 4.1B; Trodelvy +42%; HIV prevention nearly doubled Product sales guide raised to USD 31.0–31.3B; four 2026 acquisitions
Regeneron USD 5.1B (+36%) Dupixent sales USD 6.5B (+35%); EYLEA HD +62%; Libtayo +51% Expanded Sanofi antibody collaboration (Oct 2026)
Vertex USD 3.44B (+12%) Cystic fibrosis franchise; Casgevy USD 99M; Journavx USD 58M Revenue guide raised to USD 13.15–13.25B; Crinetics acquisition
Moderna USD 1.3B (+29%) mRNA flu vaccine approved Aug 2026 Revenue growth guide raised to 15–25%; cancer vaccine filing planned
BioNTech EUR 1.29B Oncology pivot with BMS on pumitamig Revenue guide EUR 1.7–1.9B; seven pivotal pumitamig trials

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Three patterns stand out. First, companies with newer growth products are offsetting losses on older ones: Amgen's Prolia and Xgeva fell sharply as biosimilars launched, while Repatha, Evenity, Tezspire and Imdelltra grew strongly. Second, immunology and HIV remain major profit engines, as Dupixent's 35% growth and Gilead's 18% HIV growth show. Third, new modalities are starting to earn revenue: Vertex's gene-edited Casgevy grew almost six-fold year on year, and Moderna has added an mRNA flu vaccine.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Investments and Deals



Figure 3: Biotech Dealmaking in 2026, Selected Transactions

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Acquirer / Partner Target Value Focus
Gilead Sciences Arcellx, Tubulis, Ouro Medicines, PepStar About USD 12.7B upfront (IPR&D charges USD 12.4B) Cell therapy, ADCs, immunology
Sun Pharma Organon USD 11.75B Specialty and women's health portfolio
Eli Lilly Centessa and other 2026 deals About USD 10.8B in total Neuroscience and other areas
GSK Nuvalent USD 10.6B Lung cancer targeted therapy
Pfizer Innovent (collaboration) Up to USD 10.5B ADCs and multi-specific antibodies
Regeneron Sanofi (expanded collaboration) USD 1B upfront; up to USD 7B in milestones Long-acting antibodies
Merck & Co. Terns Pharmaceuticals About USD 6.7B Chronic myeloid leukemia
Biogen Apellis Pharmaceuticals USD 5.6B upfront Immunology and rare disease

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Large companies are spending heavily for three reasons: patent expiries on major products later this decade, strong cash flows, and the availability of late-stage assets in oncology, immunology and neuroscience. R&D budgets are also rising, with Amgen's third-quarter R&D up 11% and Regeneron guiding to more than USD 6 billion in annual R&D.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Company Developments



Figure 4: Top Biotechnology Company Moves, 2026

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

mRNA is moving into cancer and flu. Moderna and Merck reported positive Phase 3 results for intismeran autogene, an individualized mRNA cancer vaccine, which cut the risk of melanoma recurrence or death by 42% when added to Keytruda. Moderna's mRNA flu vaccine was approved by the FDA in August 2026.

What it indicates: mRNA platforms are diversifying beyond COVID-19, opening new revenue for Moderna, BioNTech and their partners.

Gene editing and cell therapy are scaling. Vertex's Casgevy earned USD 99 million in the third quarter, nearly six times the prior year, and Gilead agreed to acquire Arcellx to gain full control of its CAR-T therapy for multiple myeloma.

What it indicates: Advanced therapies are moving from launch to growth, rewarding companies with manufacturing and treatment-center networks.

Biotechs are pivoting to oncology. BioNTech is running seven pivotal trials of pumitamig, a PD-L1×VEGF-A bispecific developed with Bristol Myers Squibb, while its COVID-19 vaccine revenue declines.

What it indicates: Oncology remains the largest destination for biotech investment, and bispecifics are a key next-generation format.

Collaborations are expanding. Regeneron and Sanofi added next-generation long-acting antibodies to their collaboration in October 2026, building on Dupixent's success.

What it indicates: Proven partnerships are being extended to protect and grow immunology franchises.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Market Drivers

  • Rising demand for biologics gene therapy
  • Advances in genomics proteomics drug discovery
  • Large pharma cash flows funding acquisitions ahead of patent expiries.
  • Growth of personalized medicine
  • Expansion of biotech in Asia Pacific, the fastest-growing region.

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    Major Challenges

    • Biosimilar competition eroding older biologics, as seen with Prolia and Xgeva.
    • High R&D costs and late-stage trial failures.
    • Drug pricing pressure in the U.S. and Europe.
    • Complex manufacturing for cell and gene therapies.
    • Falling COVID-19 vaccine revenue for mRNA companies.

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    Emerging Opportunities

    • Bioinformatics and AI tools, the fastest-growing application.
    • Oncology bispecifics, ADCs and cancer vaccines.
    • Long-acting antibodies in immunology and respiratory disease.
    • Gene editing and CAR-T as treatment networks expand.
    • Asia Pacific partnerships and licensing.

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    Company Ecosystem



    Figure 5: Biotechnology Company Ecosystem, 2026

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    The supply side includes large biotechnology companies, pharma buyers and partners, and the tools, CDMO and service providers that support research and manufacturing. The demand side includes healthcare providers, payers and governments, agriculture and industrial users, and research buyers such as universities and public agencies.

    Customer and Buyer Intelligence

    Target Account Group Decision-Makers Purchase Signals Commercial Opportunity
    Pharma business development Head of BD, R&D Head Patent expiries, pipeline gaps Acquisition and licensing targets
    Biotech companies CEO, CFO, CSO Funding needs, late-stage data Partnering and exit planning
    CDMOs and tools providers BD and Commercial Heads New modalities, capacity needs Manufacturing and research supply
    Investors Portfolio Managers Results, deals, trial readouts Valuation and pipeline benchmarking
    Governments and payers Health Policy and HTA Leads New approvals, pricing reform Access and reimbursement planning

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    How Precedence Research Supports Decision-Making

    Master Dataset provides company, segment and regional data for biotechnology and adjacent markets such as the biopharmaceutical U.S. biotechnology red biotechnology

    Precedence Quadrant ranks biotechnology companies on revenue growth, pipeline strength, deal activity and patent exposure, helping business development teams and investors screen leaders and targets.

    Interactive Intelligence Dashboard tracks quarterly results, acquisitions, approvals and trial readouts, so strategy teams can respond to competitor moves quickly.

    Quality & Manufacturing Intelligence maps biologics, cell and gene therapy and mRNA manufacturing capacity, supporting sourcing and partnering decisions.

    Customized Research answers specific questions, such as acquisition target screening, deal valuation benchmarks or competitor pipeline analysis.

    Solution What It Provides How It Helps
    Master Dataset Company, segment and region data on biotechnology Benchmarks companies and segments
    Precedence Quadrant Ranking on growth, pipeline and deals Screens leaders and acquisition targets
    Interactive Dashboard Live tracking of results, deals and approvals Times BD and investment moves
    Quality & Manufacturing Intelligence Biologics, cell/gene and mRNA capacity mapping Supports manufacturing partner choices
    Customized Research Target screening and valuation studies Answers decision-specific questions

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    Why Continuously Updated Intelligence Matters

    Biotech company positions change with every quarter's results, deal and trial readout. Monthly updates suit business development teams tracking deals and data. Quarterly updates match company earnings, such as Amgen, Gilead and Regeneron results. Six-monthly updates align with major medical meetings and regulatory decisions, and annual updates support investors reviewing market size and company share. Precedence Research offers all four update cycles.

    Strategic Outlook

    • CEOs and CXOs: the market triples to USD 6.34 trillion by 2035; leaders are using strong 2026 cash flows to buy growth before patent expiries.
    • Strategy and business development teams: 2026 deals of USD 5–13 billion set valuation benchmarks for late-stage oncology, immunology and cell therapy assets.
    • R&D leaders: bispecifics, ADCs, mRNA cancer vaccines, gene editing and long-acting antibodies are the key growth modalities.
    • Procurement and manufacturing teams: secure capacity for complex biologics and advanced therapies early.
    • Investors: biotechs with late-stage assets in oncology and immunology remain prime acquisition targets.
    • Tools and service suppliers: rising R&D budgets and the fastest growth in bioinformatics support demand.

    Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

    Call to Action

    To compare the top biotechnology companies and track their investments and pipelines, explore the full report or speak with a Precedence Research analyst.

    • Report:
    • Request a sample:
    • Schedule a meeting:

    Fill out the form for relevant samples, case studies, and examples. ...

    Related Reports

  • U.S. Biotechnology Market:
  • Red Biotechnology Market:
  • Biotechnology Reagents and Kits Market:
  • Biotechnology and Pharmaceutical Services Outsourcing Market:
  • Biotechnology Instruments Market:
  • Biopharmaceutical Market:
  • Biologics Market:
  • Gene Therapy Market:
  • Bioinformatics Market:
  • Drug Discovery Market:
  • Personalized Medicine Market:
  • Genomics Market:
  • Proteomics Market:
  • Microfluidics Market:
  • Clinical Trials Market:
  • Oncology Market:
  • Immunology Market:
  • Neurology Market:
  • Biopesticides Market:
  • Artificial Intelligence Market:

    About Precedence Research

    Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, biotechnology, pharmaceuticals, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.

    Our Partners

    • Towards Healthcare:
    • Towards Packaging:
    • Towards Chemical & Materials:

    Connect With Us

    • USA: +1 804 441 9344
    • APAC: +61 485 981 310 or +91 87933 22019
    • Singapore: +65 3105 1271
    • Europe: +44 7383 092 044
    • Email:...

    Social Media

    • LinkedIn:
    • Facebook:
    • X:
    • Medium:

MENAFN17112026004107003653ID1111976673


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search